KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) FCF Margin (2016 - 2025)

Historic FCF Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 127.42%.

  • TherapeuticsMD's FCF Margin rose 1404000.0% to 127.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 74.96%, marking a year-over-year increase of 3135000.0%. This contributed to the annual value of 66.44% for FY2024, which is 18391700.0% up from last year.
  • Per TherapeuticsMD's latest filing, its FCF Margin stood at 127.42% for Q3 2025, which was up 1404000.0% from 40.02% recorded in Q2 2025.
  • TherapeuticsMD's FCF Margin's 5-year high stood at 5004.52% during Q3 2022, with a 5-year trough of 11373.58% in Q3 2023.
  • Its 5-year average for FCF Margin is 948.75%, with a median of 73.16% in 2024.
  • In the last 5 years, TherapeuticsMD's FCF Margin plummeted by -163781000bps in 2023 and then soared by 113606100bps in 2024.
  • Quarter analysis of 5 years shows TherapeuticsMD's FCF Margin stood at 257.0% in 2021, then crashed by -83bps to 44.1% in 2022, then plummeted by -2341bps to 988.05% in 2023, then surged by 100bps to 2.55% in 2024, then surged by 4899bps to 127.42% in 2025.
  • Its FCF Margin stands at 127.42% for Q3 2025, versus 40.02% for Q2 2025 and 177.86% for Q1 2025.